Legend Innovation Life Science Fund Announces Investment Commitment of Up to $50 Million in Mid-Atlantic BioTherapeutics, Inc.
The investment will support MABT’s continued clinical development, research initiatives, and regulatory milestones. The first funding tranche is expected in Q3 2025, marking a new chapter of growth for the company. MABT plans to initiate Phase 3 clinical trial for its lead viral encephalitis drug in 2026 and advance new......